Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CARsgen Therapeutics Holdings Limited (2171.HK)
Shanghai, CN
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +6.47% | +6.65% | -16.16% | +28.08% | +4.14% | +21.95% | -11.01% | +63.45% | -39.63% | -39.63% | -39.63% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+218.7% ★
-
EPS growth Biotechnology: +29.7%+87.5% ★ Q4'25: -13,400.0% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+15.9% Q4'25: +0.0% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-181.4% Q4'25: -116.3% (vs Q4'23)
-
ROIC Biotechnology: -16.1%— Q4'25: +122.8% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-0.2% ★ Q4'25: -0.7% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.30× Q4'25: -0.16× (vs Q4'23)
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
est: 5.90M (-100.0%)
|
39.43M
est: 112.29M (-64.9%)
|
125.66M
est: 118.95M (+5.6%)
|
728.25M
351.36M – 1.11B
+512.2% YoY
|
1.68B
840.18M – 2.51B
+130.1% YoY
|
2.48B
2.44B – 2.52B
+47.8% YoY
|
| EBITDA |
-717.64M
est: -1.18M (-60,742.8%)
|
-686.61M
est: -22.46M (-2,957.3%)
|
-203.91M
est: -23.79M (-757.1%)
|
-145.65M
-221.03M – -70.27M
-512.2% YoY
|
-335.10M
-502.16M – -168.04M
-130.1% YoY
|
-495.43M
-503.21M – -487.65M
-47.8% YoY
|
| EBIT |
-785.05M
est: -1.18M (-66,458.0%)
|
-751.75M
est: -22.46M (-3,247.3%)
|
-227.90M
est: -23.79M (-857.9%)
|
-145.65M
-221.03M – -70.27M
-512.2% YoY
|
-335.10M
-502.16M – -168.04M
-130.1% YoY
|
-495.43M
-503.21M – -487.65M
-47.8% YoY
|
| Net Income |
-747.79M
est: -646.38M (-15.7%)
|
-798.13M
est: -476.22M (-67.6%)
|
-97.86M
est: -715.75M (+86.3%)
|
-72.61M
-85.89M – 252.66M
+89.9% YoY
|
693.69M
229.03M – 1.16B
+1,055.3% YoY
|
1.18B
251.94M – 2.11B
+69.9% YoY
|
| SGA |
133.31M
est: 9.94M (+1,241.0%)
|
52.02M
est: 189.29M (-72.5%)
|
26.07M
est: 200.52M (-87.0%)
|
1.23B
592.28M – 1.86B
+512.2% YoY
|
2.82B
1.42B – 4.23B
+130.1% YoY
|
4.18B
4.11B – 4.24B
+47.8% YoY
|
| EPS |
-1.34
est: -1.16 (-15.5%)
|
-1.44
est: -1.25 (-14.8%)
|
-0.18
est: -1.30 (+86.1%)
|
0.15
-0.16 – 0.46
+111.6% YoY
|
1.26
0.41 – 2.10
+731.9% YoY
|
2.14
0.46 – 3.81
+69.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.48% | 312.3K | 0.59% |
| 2 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.06% | 44.4K | 0.74% |
| 3 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.05% | 365.1K | 0.65% |
| 4 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.04% | 150.1K | 0.74% |
| 5 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.04% | 154.4K | 0.72% |
| 6 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.04% | 236.0K | 0.55% |
| 7 | State Street SPDR S&P China ETF GXC | 0.03% | 115.1K | 0.59% |
| 8 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.02% | 2.97M | 0.06% |
| 9 | iShares MSCI EM IMI Screened UCITS ETF SEDM.L | 0.01% | 102.3K | 0.18% |
| 10 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.01% | 221.9K | 0.26% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Huamao Wang | Co-Founder, Chief Operating Officer & Executive Director | 2M | — |
| Zonghai Li | Co-Founder, Chief Executive Officer, Chief Scientific Officer & Chairman of the Board | 2M | — |
| Hua Jiang | Executive Director | 1M | — |
| Haiou Chen | Executive Vice President | — | male |
| Wing Yat Lui | Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2171.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
